Use of Biologic Therapies With Different Mechanisms of Action (MOA) in the First-line (1L) Treatment of Crohn's Disease (CD) in the US

被引：0

作者：

Huang, Zhongwen ^{[1
]}

Ba, Yi ^{[1
]}

Kamble, Pravin ^{[1
]}

Wang, Song ^{[1
]}

机构：

[1] Takeda, Cambridge, MA USA

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2021年 / 116卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

S917

引用

页码：S433 / S433

页数：1

共 50 条

[41] Treatment characterization and decision-making strategy for first-line pharmacological motor symptomatic therapies in Parkinson's disease [J].

Javidnia, M. ;

Jones, J. ;

Ertefaie, A. ;

Venuto, C. .

MOVEMENT DISORDERS, 2020, 35 :S457-S458

[42] Use and impact of immunomodulator cotherapy with first-line and second-line antitumor necrosis factor agents in Crohn's disease and ulcerative colitis [J].

Pudipeddi, A. ;

Paramsothy, S. ;

Leong, R. .

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 :122-123

[43] Economic and clinical burden of chronic corticosteroid use in patients with Crohn[apos]s disease initiated on biologic or conventional therapies in the US: A retrospective claims study [J].

Zhdanava, Maryia ;

Zhao, Ruizhi ;

Manceur, Ameur M. ;

Ding, Zhijie ;

Boudreau, Julien ;

Kachroo, Sumesh ;

Kerner, Caroline ;

Izanec, James ;

Pilon, Dominic .

JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2024, 64 (02) :386-394.e10

[44] First Head-to-Head Study in Crohn's Disease supports the Use of Ustekinumab as a First-line Biological in Biological-naive Patients [J].

不详 .

VISCERAL MEDICINE, 2021, 37 (04) :326-326

[45] Patient profiles as drivers of physician choice for first-line (1L) treatment (tx) in locally advanced or metastatic urothelial cancer (la/mUC): Perspectives from a US study. [J].

Milloy, Neil ;

Walley, Maria ;

Simpson, Amber ;

Forshaw, Cameron ;

Morris, Valerie A. ;

Kearney, Mairead .

JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)

[46] Real-world first-line (1L) treatment patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a US health insurance database. [J].

Swami, Umang ;

Hong, Agnes ;

El-Chaar, Nader N. ;

Nimke, David ;

Ramaswamy, Krishnan ;

Bell, Elizabeth J. ;

Sandin, Rickard ;

Agarwal, Neeraj .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[47] Treatment modification with sunitinib in first-line (1L) metastatic renal cell carcinoma (mRCC): An analysis of the STAR-TOR registry. [J].

Boegemann, Martin ;

Hubbe, Marcus ;

Thomaidou, Despina ;

Blackburn, Stuart ;

Bent-Ennakhil, Nawal ;

Wood, Robert ;

Bargo, Danielle .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)

[48] Assessing Adoption of Standard of Care and Comparing Clinical and Demographic Differences in First-Line (1L) Treatment (Tx) of Chronic Lymphocytic Leukemia (CLL) [J].

Hou, Jing-Zhou ;

Gart, Michael ;

Vasudevan, Anupama ;

Katzen, Harvey I. ;

Choksi, Rushir ;

Blanc, Simon .

BLOOD, 2023, 142

[49] Prognostic factors for patients with advanced renal cell carcinoma (aRCC) in the era of first-line (1L) treatment with immune checkpoint inhibitors (ICIs). [J].

Mantia, Charlene ;

Jegede, Opeyemi ;

Regan, Meredith M. ;

Atkins, Michael B. ;

McDermott, David F. .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

[50] The impact of obesity on treatment outcomes in patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents [J].

Gan, C. L. ;

Meyers, D. E. ;

Stukalin, I. ;

Dudani, S. ;

Dolter, S. ;

Grosjean, H. A. I. ;

Ewanchuk, B. W. ;

Goutam, S. ;

Sander, M. ;

Wells, J. C. ;

Pabani, A. ;

Cheng, T. ;

Yuasa, T. ;

Morris, D. ;

Kanesvaran, R. ;

Pal, S. K. ;

Wood, L. A. ;

Donskov, F. ;

Choueiri, T. K. ;

Heng, D. Y. C. .

ANNALS OF ONCOLOGY, 2020, 31 :S1408-S1408

← 1 2 3 4 5 →